Question:
COX-2 SELECTIVE INHIBITOR •withdrawn from the market due to HIGH INCIDENCE OF CARDIOVASCULAR THROMBOTIC events
Author: LEIGHTON DWIGHT OBILLOSAnswer:
Rofecoxib & Valdecoxib
0 / 5 (0 ratings)
1 answer(s) in total
Author
LEIGHTON DWIGHT OBILLOS